Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The PrEPVacc trial is unlikely to show that experimental vaccine regimens can prevent HIV.
While IAS is disappointed at this outcome, we believe that this provides us with lessons to drive HIV vaccine R&D with urgency.
The HIV response is a shared global commitment to equitable health outcomes.
So far, traditional HIV vaccines that stimulate the production of antibodies have failed in large trials.
The late HIV epidemiologist founded the House of Marc Jacobs.
The vaccine, dubbed VIR-1388, is designed to stimulate the production of T cells to fight HIV.
An epidemiologist who addressed HIV and COVID-19 disparities, Stephaun Elite Wallace loved music and founded the House of Marc Jacobs.
NIH’s Carl Dieffenbach and Bill Kapogiannis interview experts about research presented at IAS 2023.
HIV.gov’s coverage of the conference began with two video conversations looking ahead to the exciting research that will be presented.
The experimental vaccine regimen trains the immune system to produce broadly neutralizing antibodies that target HIV.
An efficacious, long-lasting and cost-effective vaccine could accelerate the decline of HIV incidence in high-burden countries.
HVAD 2023 honors the many individuals advancing HIV vaccine research.
Researchers are exploring novel strategies to help the immune system produce broadly neutralizing antibodies.
AVAC looks ahead with Anthony Fauci, MD, to what’s next in the fight against HIV and COVID-19.
Researchers halt the Mosaico study after an experimental vaccine was found to be safe but not effective against HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.